Prostate cancer cells

Cell line developed for study of androgen resistance development in prostate cancer cells

  • Research use only
  • Non-exclusive licenses available


Licensing Manager: Matt Boehm, Ph.D. or 402-559-2166.

SKU: 080 Categories: , Tags: , ,


Cell line developed for study of androgen resistance development in prostate cancer cells

Prostate cancer is usually treated with watchful waiting, surgery, radiation therapy, chemotherapy, cryosurgery, hormonal therapy, or some combination. Hormonal therapy uses medications such anti-androgens to block prostate cancer cells from getting dihydrotestosterone, a hormone produced in the prostate and required for the growth and spread of most prostate cancer cells. However use of anti-androgens is limited by rapidly acquired within few months’ resistance of prostate cancer cells to hormonal therapy.
Researchers at University of Nebraska Medical Center have discovered that induced expression of cellular Prostatic Acid Phosphatase inhibits the tumor resistance to androgen deprivation therapy, restoring and prolonging therapy effect and observed that reduced cellular Prostatic Acid Phosphatase expression in cancer cells leads to prostate cancer progression, which can be used as a long-term prediction hormonal therapy success and diagnosis of prostate cancer.
Scientists at UNMC then developed a novel cell line which mimics the stages of resistance to androgen therapy for study of the molecular mechanisms by which androgen therapy sensitive prostate cancer cells differentiate to androgen resistant cancer cells.
This technology will allow the generation of entirely novel methods for screening, treatment and prevention of androgen resistant prostate cancer.
To discuss licensing opportunities please contact Matt Boehm, Ph.D., at or 402-559-2166.